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Abstract The small G protein adenosine diphosphate ribosyla-
tion factor-1 (ARF1) is activated by cell membrane binding of a
self-folding N-terminal domain. We present a model of the hu-
man ARF1 N-terminal peptide in planar lipid bilayers, deter-
mined from neutron lamellar di¡raction and circular dichroism
data with molecular modelling. This amphipathic domain lies at
a shallow membrane depth, ideal for regulation of the ARF1
bio-timer by rapid, reversible membrane binding. The helical
region does not elongate upon membrane binding, leaving the
connecting £exible linker region’s length unchanged.
( 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Adenosine diphosphate ribosylation factors (ARFs) form a
family of small intracellular G proteins that become activated
and function only on membrane surfaces. To accomplish this,
they combine the characteristic GDP/GTP switch with a
unique membrane/cytoplasm switch. Membrane binding is
also crucial to the normal biological regulation of ARFs by
their guanine exchange factor (GEF) proteins and GTPase
activating proteins (GAPs).
A number of crystal structures have been published for the
soluble, inactive forms of certain ARF proteins (e.g. [1,2]).
Much less is known about the active, membrane bound struc-
tures of ARF, the details of which are crucial to our under-
standing of how these proteins function both as molecular
switches and bio-timers in cells. The highly conserved N-ter-
minal domain primarily controls the membrane binding of
ARF1. It consists of an N-terminal myristoyl chain (Myr)
linked to a self-folding peptide domain. Membrane binding
by active ARF-GTP persists upon removal of Myr, but is
completely abolished upon deletion of the N-terminal peptide
[3]. Furthermore, a double mutation reducing the hydropho-
bicity of the N-terminal peptide accelerates dissociation of
active ARF-GTP from membranes by 100-fold [4].
The membrane-binding domain is a helix assumed to lie
approximately parallel to the membrane surface. The interac-
tion of this domain of human ARF1 with membrane lipids is
an early event in the multi-step ARF1 activation pathway [5].
Indeed, membrane binding is a necessary precursor to the
large structural reorganisations of the core and switch regions
of ARF1, which permit its activation by the appropriate
GEFs (e.g. [6]). Membrane insertion of the N-terminal helix
of ARF1 would facilitate a change to the open conformation
that is required for ARF1 to bind its GEF [7].
The structural details of the membrane ARF1-GEF inter-
mediates are not known. The helical region within the N-ter-
minal domain of ARF1 may elongate upon membrane asso-
ciation [1]. Changes in the length of the helix, and thus the
connecting £exible linker region, could a¡ect the molecular
reorganisation of the core and switch regions of ARF1 that
occur along this pathway. Di¡erences in the length of the
£exible linker regions of ARF1 and ARF6 may contribute
to the di¡erences seen in the switch regions of these two
ARF isoforms, which are thought to play an important phys-
iological role [2]. To understand this role as a reversible mem-
brane anchor, it is necessary to know the precise depth and
orientation of the N-terminal peptide domain within a lipid
bilayer. Here we present the directly observed location of
three residues of ARF1’s self-folding N-terminal peptide do-
main in planar phospholipid bilayers. From this we deduce
the orientation, depth and probable structure of the peptide in
the membrane.
2. Materials and methods
DOPC and DOPG were purchased from Avanti Polar Lipids (Bir-
mingham, AL, USA). The 15 residue ARF1 peptide was synthesised
and puri¢ed by Albachem (Edinburgh, UK) to the sequence in the
Swiss Protein Data Bank. Four batches of the peptide were produced,
one undeuterated and three deuterium-labelled at phenylalanines 5, 9
or 13. Each label involved replacing the 5 ring hydrogens with deu-
terium. 20 mg of DOPC and DOPG (70:30 mol%) and 3 mol% pep-
tide were co-dissolved in chloroform/tri£uoroethanol (TFE) and de-
posited by airbrush onto a silicon wafer. This produces highly aligned
multi-bilayers in a standard manner. The wafers were placed under
vacuum for 12 h to remove all traces of the solvent, before being
rehydrated and annealed at 40‡C in a humid atmosphere for at least
6 h. Samples were then mounted and aligned in sample cans 24 h
before commencing data collection to allow full equilibration with
the chosen sample conditions.
Neutron di¡raction measurements were carried out on the V1 dif-
fractometer at BENSC, Hahn-Meitner-Institut, Berlin, Germany.
Samples were run at 25‡C and the temperature was regulated by a
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circulating water bath. Small water baths containing saturated solu-
tions of potassium chloride, potassium nitrate or potassium sulphate
were placed inside the sample can to maintain the relative humidity of
the sample environment at 85%, 92% or 97% respectively. Each sam-
ple was run at three 2H2O concentrations, 8%, 20% or 29%, and 50%
2H2O to provide additional phasing information. 8% 2H2O data were
used for the di¡erence calculations, since water of this isotopic com-
position has a net neutron scattering length density of zero. Two or
three relative humidities were used for the 8% data; this improves
data phasing and allows determination of accurate structure factors
for the 8% data at the exact d-spacing as the 50% data [8]. The
scanning protocol consisted of sequential a (sample angle) scans
around the predicted Bragg angle for each order.
Peak ¢tting and background subtraction were carried out using
Peak¢t (Jandel Scienti¢c Software GmbH). Absorption and Lorentz
corrections were applied and the intensities square-rooted to produce
structure factor amplitudes. For each sample, the relative scaling of
the data sets representing di¡erent 2H2O concentrations and the
phases of each of their orders were determined by least-squares ¢tting
to straight line functions. The whole procedure has been described
previously [9]. The data were placed on a ‘relative absolute’ [10^12]
scale using the known neutron scattering lengths of 2H and 1H. This
method requires knowledge of the molar percentage of water in the
samples, which was determined as previously described [13]. Four
orders of di¡raction were used in the ¢tting procedure, su⁄cient to
give an accurate label position [14].
Fig. 1. Upper: (solid line) neutron scattering length density pro¢les of deuterium label in 3 mol% ARF1 N-terminal peptide in stacked multi-
layers of DOPC and DOPG, at 25‡C and 92% relative humidity, 8% 2H2O; A: (2H5-Phe13); B: (2H5-Phe9); C: (2H5-Phe5). The data have
been scaled using the relative absolute method [10^12]. (Dashed line) Gaussian models of the label residues. The position, width and size of
Gaussian distributions (Table 2) were ¢tted, in reciprocal space, to observed di¡erences in neutron structure factors. Lower: the total scattering
length density of DOPC and DOPG in the molar ratio of 7:3. The water, lipid headgroup and acyl chain regions are shown for orientation.
The unit cell length was 49.88 AQ . NB. The vertical scale di¡ers between the two panels.
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For the circular dichroism (CD) measurements, large unilamellar
vesicles (LUVs) containing 30 mol% DOPG/70 mol% DOPC were
prepared from lipid ¢lms dried under nitrogen gas and then overnight
under vacuum. The dried lipids were suspended in liposome bu¡er, 10
mM Tris, 0.1 mM EDTA, pH 7.4, vortexed vigorously and subjected
to ¢ve freeze-thaw cycles by immersion in liquid nitrogen for 2 min
and plunging into a 40‡C water bath until thawed. Samples were then
¢ltered 10 times through two stacked polycarbonate membranes, pore
size 0.1 Wm, using a high pressure extruder (Lipex Biomembranes Inc.,
Vancouver, Canada), as per the standard extrusion method of Hope
et al. [15]. A stock solution of pre-lyophilised ARF1 peptide in lipo-
some bu¡er was prepared. Peptide was added to the preformed LUVs
to give a ¢nal peptide concentration of 0.2125 mg/ml or 0.425 mg/ml,
and a lipid:peptide mole ratio of 16.5:1, 33:1 or 66:1. ARF1 peptide
was also dissolved in liposome bu¡er and 50% TFE to give ¢nal
peptide concentrations of 0.2125 mg/ml or 0.425 mg/ml.
CD spectra were recorded on a JASCO J-600 spectropolarimeter,
using a sample cell of path length 0.02 cm. Each sample was scanned
twice. The scan range was 195^260 nm, and the scan rate 10 nm/min.
Background spectra were obtained for each sample, using 50% TFE
and liposome bu¡er for the solvent studies, and LUVs at each lipid
concentration for the ARF1 vesicle-binding studies. All sample spec-
tra were thus background-corrected, as well as averaged and
smoothed.
3. Results
3.1. Neutron di¡raction
Using neutron di¡raction and speci¢c deuteration, we have
determined the location and orientation of a 15 residue pep-
tide from the N-terminus of human ARF1 (SWISSPROT
#P32889) in an aligned bilayer. Neutron structure factors
are shown in Table 1 and neutron scattering length density
pro¢les, calculated from them, are shown in Fig. 1. The upper
plots in Fig. 1 show the di¡erence in scattering length density
pro¢les between undeuterated ARF1 peptide in anionic lipid
bilayers and three ARF1 peptides labelled at positions Phe5,
Phe9, and Phe13, under the same sample conditions. The re-
sult is the distribution of deuterium labels across the bilayer
normal. All three 2H-Phe labels clearly show one discrete site
Table 1
Neutron structure factors of ARF1 peptide in bilayers of DOPC and DOPG (70:30 mol%), as used in the Fourier subtractions
F(1) F(2) F(3) F(4)
ARF1 peptide 30.782 30.606 0.473 30.189
T 8.8U1034 T 2.5U1034 T 2.9U1034 T 4.1U1034
(2H5-Phe5)-Arf1 peptide 30.925 30.676 0.550 30.219
T 5.0U1034 T 1.8U1034 T 2.6U1034 T 3.0U1034
(2H5-Phe9)-ARF1 peptide 30.931 30.707 0.555 30.213
T 5.2U1034 T 3.9U1034 T 3.9U1034 T 3.1U1034
(2H5-Phe13)-ARF1 peptide 30.891 30.578 0.470 30.197
T 8.2U1034 T 2.3U1034 T 4.0U1034 T 4.2U1034
70% DOPC, 30% DOPG 30.935 30.541 0.523 30.327
T 1.4U1033 T 2.5U1034 T 3.0U1034 T 3.2U1034
Structure factors for bilayers of DOPC and DOPG (70:30 mol%) are also shown, for comparison. Data were collected at 25‡C, 85%, 92% or
97% relative humidity and 8% 2H2O [12].
Fig. 2. CD spectra of ARF1 peptide in LUVs containing 30 mol% DOPG/70 mol% DOPC; 50% tri£uoroethanol (TFE) and aqueous bu¡er.
The spectra from peptide at two concentrations, 0.2125 mg/ml and 0.425 mg/ml, were similar.
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on each side of the bilayer, indicating that the ARF1 peptide
adopts one orientation, or location, which is within the inter-
facial region of the membrane. To ensure reliability, data on
the ARF peptide speci¢cally deuterated at position 13 were
obtained from two independent experiments.
In order to calculate the di¡erence pro¢les accurately, it is
¢rst necessary to scale the various data sets to each other. For
a pure lipid structure, it is possible to use the known neutron
scattering lengths of the phospholipid and its component parts
[10^12]. This is not always possible when a peptide is present,
because the details of the structure are not known. In these
circumstances, it is normal to use the known neutron scatter-
ing length of deuterium, introduced into the system in ex-
change for hydrogens. In this study, seven independent deu-
terium exchanges were carried out, namely the three
deuterated amino acids and 2H2O^H2O exchange with each
of the four di¡erent peptides (for method see [16]). The fact
that consistent scale factors were calculated from all seven
increases our con¢dence in the data. It also means that, by
de¢nition, the size (area under the peaks) of the label distri-
butions shown in Fig. 1A^C is exactly right for the number of
deuterons in each of the samples measured.
The neutron scattering length density pro¢les of bilayers
with peptide can be di⁄cult to understand and of limited
interpretational value. The observed di¡erences between these
pro¢les and that of pure phospholipid are small. It is impos-
Fig. 3. The peptide models drawn as ribbon diagrams, which view the peptides along the surface of the bilayer. The diagram shows the relative
depth in the bilayer of the peptide’s K-carbons. As in Fig. 1, the water, lipid headgroup and acyl chain regions are shown for orientation. The
solid, horizontal lines indicate the measured depths of the labels. Models A and B are the two possible orientations of the peptide taken di-
rectly from the crystal structure of the full-length protein [1]. Models C and D were calculated by con¢ning the phi^psi angles of the crystal-de-
rived model to an K-helix, and then orienting to the label data. For a detailed discussion of the merits of each model, please refer to the text.
FEBS 27399 15-7-03
S.M.A. Davies et al./FEBS Letters 548 (2003) 119^124122
sible to deconstruct the changes caused by scattering from the
peptide itself from the changes in scattering caused by the
redistribution of the phospholipids necessary to accommodate
the peptide. The situation is made more complex by the arte-
facts introduced by termination error. The di¡erence method,
as used to produce the pro¢les shown in Fig. 1A^C, simpli¢es
the picture by removing the contributions of water, phospho-
lipid and undeuterated parts of the peptide. The resulting
pro¢le can be ¢tted to a single Gaussian distribution. If the
¢tting process is carried out in reciprocal space, as in this case,
the e¡ects of termination error are also avoided.
3.2. CD
It is expected that the N-terminal peptide domain of ARF1
will self-fold into its active conformation only in a membrane
environment. Fig. 2 shows the CD results, which support this
prediction. In aqueous bu¡er, the peptide’s structure was ran-
dom coil. The secondary structure promoting solvent tri£uoro-
ethanol induces some helicity, but the highest overall amount
of secondary structure was found in LUVs containing 30
mol% DOPG/70 mol% DOPC (Fig. 2). At lipid/peptide ratios
where the entire ARF1 domain was membrane bound, which
include that used for the neutron di¡raction work, estimates
of the amount of helix present in the peptide ranged from 28%
to 36% [17,18]. From the crystal structure, this domain is only
partially K-helix, the rest being non-speci¢c helix and coil that
connects to the linker region. There is no indication of a large
increase in helical conformation on membrane binding.
3.3. Modelling
The di¡erence pro¢le of neutron scattering length density
gives the time-averaged, Gaussian distribution of the centre of
mass for the ¢ve deuterons around the ring of each labelled
phenylalanine. Our goal was to ¢nd the orientation of the
ARF1 peptide such that the depth of each phenylalanine
ring in the model coincided with the data. We used the
same method previously to determine the position of a fusion
peptide within a lipid membrane [19]. As explained in that
paper, four independent labels are required to orient a protein
unambiguously. In the current case, with only three labels, we
are left with two models that must be evaluated using other
criteria.
As a starting point for modelling our data, we used the
coordinates of the N-terminal domain present in the crystal
structure of human ARF1-GDP [1]. Fig. 3A,B representates
schematically the two possible orientations from the crystal
structure model, as viewed along the surface of the membrane.
The horizontal lines indicate the depth in the bilayer of the
labels, where the vertical scale shows the bilayer pro¢le. Both
orientations indicate ARF1 lies almost exactly parallel to the
bilayer surface, at an angle of less than 5‡ from the membrane
surface, as determined by ¢tting a straight line to the back-
bone. However, orientation B is highly thermodynamically
unfavourable, because the predicted hydrophobic face of
model B is partially exposed to the water side of the lipid^
water interface. The charged lysines 15 and 16 are placed far
too deeply in the hydrophobic core of the membrane. Fur-
thermore, isoleucine 4 is unexpectedly found to be exposed to
the aqueous environment. Fig. 4 shows how model A lies
within the lipid headgroups. The lower surface in Fig. 4 rep-
resents the centre of the bilayer, and the upper surface the
hydrophobic^hydrophilic interface.
To test the idea that the N-terminal helix extends past res-
idue 13 upon binding to the membrane, we used the Sybyl
Fig. 4. The molecular structure of ARF1 peptide oriented in one
half of a bilayer. The vertical line is the z-axis scale parallel to the
membrane normal. The lower lattice represents the centre of the bi-
layer, and the upper lattice at the approximate value of 16 AQ sug-
gests the hydrophobic/hydrophilic interface. The peptide helix is rep-
resented as a coiled ribbon, while the deuterated residues Phe5,
Phe9, and Phe13 are represented as stick models. This orientation is
model A in Fig. 2, and is the best ¢t to the experimental data. The
¢gure was prepared with Molscript [22] and Raster3D [23].
Table 2
Gaussian models of deuterium label distribution of 3.0% (mol) (2H5-Phe5)-, (2H5-Phe9)- and (2H5-Phe13)-ARF1 peptide in bilayers of DOPC
and DOPG (70:30 mol%)
Phe5 Phe9 Phe13
Amplitude 0.0551T 2.4U1034 0.0555T 3.9U1034 0.0520T 3.7U1034
Positiona 17.99T 1.9U1032 AQ 16.68T 3.6U1032 AQ 22.06T 5.6U1032 AQ
Widthb 5.83T 3.0U1032 AQ 6.64T 4.3U1032 AQ 5.88T 7.9U1032 AQ
Chi-squared 2.1U1035 7.2U1035 7.0U1036
The position, width and size of Gaussian distributions were ¢tted, in reciprocal space, to di¡erence neutron structure factors. Four orders of
di¡raction were used in the ¢tting procedure.
aThe position of each label site is expressed as distance from the centre of the bilayer.
bThe width is the full width at 1/e height.
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modelling software (Tripos) and constrained the phi, psi an-
gles of the crystal structure model to those of an K-helix. We
then performed 1000 steps of energy minimisation to remove
forbidden contacts that might have been created. Fig. 3C,D
shows that this new model is substantially tilted out of the
membrane plane, to an angle of about 20‡. This orientation
lifts leucines 8 and 12 unacceptably out of the bilayer (model
C), or pushes lysines 15 and 16 even further into the bilayer
(model D). Furthermore, an ab initio K-helix constructed
from the sequence cannot be oriented to ¢t the data at all.
When constrained to a helix, the Phe13 moves closer to the
same face of the peptide as Phe5 and Phe9, and therefore
cannot bridge the large measured gap between these residues.
Combining these ¢ndings with the CD data, which indicates
that the membrane bound peptide is not completely helical,
we believe that the helix must be terminated before residue 13
of the ARF1 N-terminal domain, and does not extend upon
membrane binding.
Each panel of Figs. 3 and 4 also shows the corresponding
hydrophobic vector, de¢ned as the vector between the hydro-
phobic and hydrophilic barycentres [20]. The barycentres were
calculated by the method and transfer energies of Brasseur
[20].
4. Discussion
Reversible membrane binding regulates many proteins and
enzymes involved in cell signalling; for a recent review see
[21]. Little is known about how membrane binding regulates
the function of these amphitropic proteins; detailed structural
information is a prerequisite to understanding this process.
Our neutron di¡raction studies provide unique direct informa-
tion on the nature of the interaction of the ARF1 N-terminal
peptide with £at lipid membranes that resemble biological
membranes in their packing properties. From these results,
it seems likely that the ARF1 self-folding N-terminal domain
changes its internal structure very little during the membrane^
cytoplasm cycle of the ARF protein. If we model the structure
of the N-terminus as in the soluble, inactive ARF1-GDP pro-
tein and ¢t it to our label positions for ARF1 when mem-
brane bound, the peptide lies almost exactly parallel to the
membrane surface. This nicely agrees with thermodynamic
predictions. Conversely, extending the helix such that it in-
cludes the last label in our peptide, Phe13, cannot be sup-
ported by the data. Thus we believe that the helix of ARF1
does not extend upon membrane binding. This also leaves the
proximal portion of the ensuing linker region unchanged in
length. This may be important to allow the remainder of the
ARF protein su⁄cient structural £exibility to interact simul-
taneously with the cell membrane, a GEF protein, GDP/GTP
and a GAP protein ^ a remarkable feat indeed!
Acknowledgements: We thank Thomas Gutberlet and Silvia Dante for
expert technical assistance with V1 at the HMI, Nicholas Price and
the BBSRC for access to the Scottish Circular Dichroism centre.
Support for use of the BENSC facilities at the HMI was provided
by the European Commission, under the Human Potential Program-
me’s Access to Research Infrastructures action. S.M.A.D. was a Well-
come Trust International Fellow.
References
[1] Amor, J.C., Harrison, D.H., Kahn, R.A. and Ringe, D. (1994)
Nature 372, 704^708.
[2] Me¤ne¤trey, J., Macia, E., Pasqualato, S., Franco, M. and Cher¢ls,
J. (2000) Nat. Struct. Biol. 7, 466^469.
[3] Franco, M., Chardin, P., Chabre, M. and Paris, S. (1993) J. Biol.
Chem. 268, 24531^24534.
[4] Antonny, B., Be¤raud-Dufour, S., Chardin, P. and Chabre, M.
(1997) Biochemistry 36, 4675^4684.
[5] Be¤raud-Dufour, S., Paris, S., Chabre, M. and Antonny, A. (1999)
J. Biol. Chem. 274, 37629^37636.
[6] Goldberg, J. (1998) Cell 95, 237^248.
[7] Roth, M.G. (1999) Trends Cell Biol. 9, 174^179.
[8] Darkes, M.J.M. and Bradshaw, J.P. (2000) Acta Crystallogr. D
56, 48^54.
[9] Du¡, K.C., Gilchrist, P.J., Saxena, A.M. and Bradshaw, J.P.
(1994) Virology 202, 287^293.
[10] Wiener, M.C., King, G.I. and White, S.H. (1991) Biophys. J. 60,
568^576.
[11] Wiener, M.C. and White, S.H. (1991) Biophys. J. 59, 162^185.
[12] Jacobs, R.E. and White, S.H. (1989) Biochemistry 28, 3421^3437.
[13] Bradshaw, J.P., Davies, S.M.A. and Hauss, T. (1998) Biophys. J.
75, 889^895.
[14] Gordeliy, V.I. and Chernov, N.I. (1997) Acta Crystallogr. D 53,
377^384.
[15] Mayer, L.D., Hope, M.J. and Cullis, P.R. (1986) Biochim. Bio-
phys. Acta 858, 161^168.
[16] Bradshaw, J.P., Davies, S.M.A. and HauM, T. (1998) Biophys. J.
75, 889^895.
[17] Sreerama, N. and Woody, R.W. (1993) Anal. Biochem. 209, 32^
44.
[18] Bohm, G., Muhr, R. and Jaenicke, R. (1992) Protein Eng. 3,
191^195.
[19] Bradshaw, J.P., Darkes, M.J.M., Harroun, T.A., Katsaras, J.
and Epand, R.M. (2000) Biochemistry 39, 6581^6585.
[20] Brasseur, R. (2000) Mol. Membr. Biol. 17, 31^40.
[21] Johnson, J.E. and Cornell, R.B. (1999) Mol. Membr. Biol. 16,
217^235.
[22] Kraulis, P.J. (1991) Appl. Crystallogr. 24, 946^950.
[23] Merritt, E.A. and Bacon, D.J. (1997) Methods Enzymol. 277,
505^524.
FEBS 27399 15-7-03
S.M.A. Davies et al./FEBS Letters 548 (2003) 119^124124
